B
Bhabani Mohanty
Researcher at Cancer Research Institute
Publications - 16
Citations - 160
Bhabani Mohanty is an academic researcher from Cancer Research Institute. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 6, co-authored 9 publications receiving 87 citations.
Papers
More filters
Journal ArticleDOI
Agricultural Modernisation in Rural Orissa: Land Transfer and Ownership Pattern:
TL;DR: In this paper, an examen des changements agraires a l'oeuvre dans l'Etat indien d'Orissa montre une tendance a la polarisation de la structure fonciere, i.e., les mesures de modernisation profitent aux proprietaires les plus riches, qui consolident la valorisation de leurs terres, elles poussent les plus pauvres a vendre des terres qui n'assurent plus la securite economique.
Journal ArticleDOI
Direct evidence of cellular transformation by prion-like p53 amyloid infection.
Ambuja Navalkar,Satyaprakash Pandey,Namrata Singh,Komal Patel,Debalina Datta,Bhabani Mohanty,Sachin V. Jadhav,Pradip Chaudhari,Samir K. Maji +8 more
TL;DR: In this article, the authors conclusively demonstrate that wild-type p53 amyloid formation imparts oncogenic properties to non-cancerous cells, contributing to enhanced survival, apoptotic resistance with increased proliferation and migration.
Journal ArticleDOI
Development of technetium-99m labeled ultrafine gold nanobioconjugates for targeted imaging of folate receptor positive cancers
Dheeraj Kumar,Navin Sakhare,Soumen Das,Pooja Kale,Anupam Mathur,Shubhangi Mirapurkar,Sheela Muralidharan,Pradip Chaudhari,Bhabani Mohanty,Anand Ballal,P.K. Patro +10 more
TL;DR: In vivo pharmacokinetics envisaged in the present design was achieved using the present gold functionalized NP preparation, which showed affinity towards FR positive KB cancer cell lines.
Journal ArticleDOI
ARID2 suppression promotes tumor progression and upregulates cytokeratin 8, 18 and β-4 integrin expression in TP53-mutated tobacco-related oral cancer and has prognostic implications.
TL;DR: This study is the first to demonstrate tumor suppressor role of ARID2 in TP53 mutated background indicating their cooperative role in OSCC, and also highlights its prognostic implications suggesting ARID 2 as an important therapeutic target inOSCC.
Journal ArticleDOI
Targeted nano-delivery of chemotherapy via intranasal route suppresses in vivo glioblastoma growth and prolongs survival in the intracranial mouse model
Puja Sandbhor,Jayant Sastri Goda,Bhabani Mohanty,Poonam Gera,Sandhya Yadav,Godanjali Chekuri,Pradip Chaudhari,Shilpee Dutt,Rinti Banerjee +8 more
TL;DR: The present study demonstrates the anti-glioma effect of the dual drug combination of PTX and proapoptotic HePc lipid-based transferrin receptor (TfR) targeted alternative delivery of the nanoparticulate system and indicates that the nasal delivery of targeted synergistic nanocarrier holds great promise as a non-invasive adjuvant chemotherapy therapy of GBM.